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Summary
Gitelman syndrome(Gs) is a rare autosomal recessive 
salt-losing tubulopathy of young adults, characterised 
by hypokalaemia, hypomagnesaemia, hypocalciuria and 
secondary hyperaldosteronism. Hypercalcaemia due to 
hypocalciuria in these patients is extremely rare.
a 25-year-old healthy woman was referred to the 
endocrinology clinic for evaluation of persistent 
hypokalaemia. she presented with fatigue, myalgias, 
cramps and paraesthesia. Her physical examination 
was normal. Laboratory workup revealed: K+ 2.7 meq/L 
(r.v.3.5–5.1), 24 hours urinary K+ 84.7 meq/24 hours 
(r.v.25–125), Mg2+ 0.71 mg/dL (r.v.1.6–2.6), 24 hours 
urinary Mg2+ 143.1 mg/24 hours (r.v.73–122), Ca2+ 12 
mg/dL (r.v.8.4–10.2), aldosterone 47.1 ng/mL (r.v. 4–31) 
and active renin 374.7 uUI/mL (r.v.4.4–46.1). she was 
diagnosed with Gs and was treated with spironolactone, 
oral K+ and Mg2+ supplementation. Further 
investigation confirmed hypercalcaemia due to primary 
hyperparathyroidism owing to a single parathyroid 
adenoma. Following parathyroidectomy serum calcium 
normalised.
Current knowledge favours that hypomagnesaemia in 
patients with Gs protects them from hypercalcaemia. In 
this context of multiple electrolyte imbalances, correction 
of hypomagnesaemia is a challenge and should be done 
carefully. Like in our patient, aetiology of hypercalcaemia 
should be promptly diagnosed and reversed.
BaCkground 
Gitelman syndrome (GS) was first described in 
1966 in a family characterised by hypokalaemia, 
hypomagnesaemia, hypocalciuria, metabolic alka-
losis and hyper-reninemic hyperaldosteronism.1 
It is a rare autosomal recessive salt-losing tubulop-
athy with a prevalence estimated at approximately 
1:40.000.2 It is caused by mutations of SLC12A3 
gene that encodes the sodium chloride cotrans-
porter (NCC) and magnesium channels in the thia-
zide-sensitive segment of the renal distal convoluted 
tubule.3 
GS is usually diagnosed during adolescence or 
adulthood and the clinical spectrum is wide, ranging 
from asymptomatic to severe manifestations, such 
as episodes of paralysis, seizures or cardiac arrhyth-
mias. Symptoms are related to electrolyte abnormal-
ities; however, its severity does not correlate with 
the intensity of symptoms.4 Moreover, the pheno-
type–genotype correlation is heterogeneous, since 
different phenotypes have been reported in family 
members presenting identical genetic defects.5
Hypocalciuria is a prominent feature in GS1 6; 
nevertheless, the total plasma calcium concentra-
tion has been reported to be normal.1 6 Rarely, slight 
hypercalcaemia can occur in the course of GS due to 
dehydration-induced hyperproteinaemia.6 Thereby, 
the presence of hypercalcaemia in the course of this 
disease should require further investigation.
Herein, we describe a rare case of GS associated 
with moderate to severe hypercalcaemia resulting 
in profound electrolyte imbalance. We also intend 
to report our apprehension in initial control of 
severe hypomagnesaemia in a patient with concom-
itant hypercalcaemia.
CaSe preSenTaTion
A 25-year-old Caucasian normotensive woman 
was admitted to the emergency department in 
June 2015 due to malaise, fatigue, myalgias, 
cramps, left hemiface and left upper arm paraes-
thesias. Head CT excluded intracranial lesions and 
blood tests revealed a low serum K+ of 2.9 mEq/L. 
She was referred to the Endocrinology clinic for 
evaluation of persistent hypokalaemia. She denied 
diarrhoea, abuse of diuretics, laxatives or ‘natural 
supplements’. Concerning her family history, she 
has no siblings, her parents are non-consanguin-
eous and healthy. Physical examination revealed 
depressed humour, normal body mass index (22 kg/
m2), blood pressure 110/80 mm Hg, pulse rate 82 
bpm, no stigmata of hypercortisolism and no focal 
neurological signs.
inveSTigaTionS
The patient’s laboratory findings are shown in 
tables 1 and 2.
She presented with secondary hyperaldoste-
ronism, renal wasting resulting in hypokalaemia 
and hypomagnesaemia. These laboratory findings 
associated with her normotensive profile favoured 
the diagnosis of GS. She was provided with a low 
dose of magnesium aspartate (500 mg/day) and 
oral potassium chloride progressively adjusted to 
600 mg 4 id with improvement of the symptoms
The severity of hypercalcaemia did not seem to 
be justified by hypocalciuria of GS; furthermore, 
hypophosphataemia did not fit in this context. 
Additional tests revealed Ca2+ 11.8 mg/dL, Pi 
1.9 mg/dL, PTH107.3 pg/mL (n.r. 14.8–83.1) and 
25 OH vitamin D 20.4 ng/mL (n.r. 4.8–52.8) that 
were consistent with hypercalcaemia due to primary 
hyperparathyroidism (PHPT). Abdominal CT scan 
excluded renal lesions, such nephrolithiasis. Urinary 
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metanephrines and pituitary function were normal. A cervical 
Doppler ultrasonography revealed a hypervascular, hypointense 
nodule with 19×9×9 mm at the inferior pole of left lobe of 
thyroid, between oesophagus and left carotid artery, compatible 
with parathyroid adenoma.
To confirm our clinical suspicion of GS, genetic study was 
required. The variant c.602–16G>A and the variant c.2221G>A 
(p.Gly741Arg), both in heterozygosity, were detected in 
SLC12A3 gene (figure 1). Genetic study of the parents was 
requested. The father presents the variant c.602–16G>A and 
the mother the variant c.2221G>A (p.Gly741Arg), in SLC12A3 
gene. The genetic study of the parents concluded that the vari-
ants found are in different alleles (trans), which reinforce their 
pathogenicity.
The occurrence of PHPT in a young patient also justified DNA 
analysis of HRPT2 and MEN1 genes that were both normal in 
this case.
TreaTmenT
An inferior left parathyroidectomy was performed and histolog-
ical study confirmed the diagnosis of parathyroid adenoma.
ouTCome and follow-up
Serum Ca2+ and PTH normalised after surgery (Ca2+ 9.7 mg/dL, 
PTH 5 pg/mL and Pi 4.8 mg/dL). Hypocalciuria emerged and in 
17 months of follow-up normocalcaemia persists (table 3). She 
maintained mild symptomatic hypokalaemia on oral KCl 600 mg 
6id, thus spironolactone 100 mg/day was prescribed. During the 
last 6 months, medicated with spironolactone 100 mg/day, KCl 
600 mg 2id, magnesium aspartate 1229.6 mg 4id, she presented 
serum K+ in the inferior limit of normal range. She maintains 
mild-to-moderate hypomagnesaemia which can be explained by 
poor medication adherence due to gastrointestinal intolerance 
(table 3). The patient keeps regular follow-up in our department 
with clinical and biochemical evaluation.
diSCuSSion
GS is linked to inactivating mutations in the SLC12A3 gene 
resulting in loss of function of the encoded NCC in the distal 
convoluted tubules. The clinical and biochemical picture of patients 
with GS resemble those who are on thiazide diuretics, given that 
the affected transporter is the exact target of thiazides.4 7
Table 1 Laboratory results (July 2015)
normal range 
Haemoglobin 12.9 g/L 12–15
Leucocytes 11.90×10^9/L 4.5–11
Platelets 317×10^9/L 150–450
Glucose 69 mg/dL 60–100
Urea 27 mg/dL 15–40
Creatinine 0.57 mg/dL 0.57–1.11
Glomerular filtration rate 
(GFR)>60 mL/min
Total proteins/albumin 74 g/L 60–83
Sodium (Na+) 139 mEq/L 136–145
Potassium (K+) 2.7 mEq/L 3.5–5.1
Chloride (Cl-) 97 mEq/L 98–107
Calcium (Ca2+) 12 mg/dL 8.4–10.2
Phosphorus (Pi) 1.6 mg/dL 2.3–4.7
Magnesium (Mg2+) 0.71 mg/dL 1.6–2.6
Total cholesterol 254 mg/dL <190
Aldosterone 47.1 ng/mL 4–31
Active renin 374.7 uUI/mL 4.4–46.1
Table 2 Laboratory results—24-hour urine (vol. 2300 mL)
 normal range 
K+ 84.7 mEq/24 hours 25–125
Mg2+ 143.1 mg/24 hours 73–122
Ca2+ 133 mg/24 hours 100–300
Pi 1.1 g/24 hours 0.4–1.3
figure 1 Chromatographe of the sequence: above: representation of variant c.602–16G>A; below: representation of variant c.2221G>A 
(p.Gly741Arg), both detect in SLC12A3 gene.
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Despite clinical and biochemical similarities between 
patients with GS and those on thiazide diuretic therapy,4 the 
presence of hypercalcaemia in the former group is unusual.1 5 
This fact can be explained by impaired calciotropic hormones 
due hypomagnesaemia in patients with GS.6 Bianchetti et al 
demonstrated a blunted relationship between PTH, ionised 
calcium concentration and calcitriol in patients with GS 
providing evidence that these patients have a disturbed secre-
tion of PTH.6 Moreover in GS, normal levels of both plasma 
phosphate and urinary fractional phosphate excretion rule out 
PTH hyperfunction.4 6
We described a rare case of a young woman with GS 
presenting with hypercalcaemia due to PHPT. In PHPT, hyper-
calcaemia results from inappropriate hypersecretion of PTH 
from parathyroid gland(s). PTH increases tubular reabsorption 
of calcium in the kidney, stimulates release of skeletal calcium 
stores and upregulates 1α- hydroxylase resulting in increased 
1,25-(OH)2D3 production and intestinal calcium absorption.8
The differential diagnosis between PHPT and familial hypo-
calciuric hypercalcaemia should be considered because the latter 
is a benign condition. In a patient with GS, this differentiation 
is difficult because of inherent hypocalciuria. In our patient, the 
diagnosis of PHTP was sustained by concomitant hypophospha-
taemia, high levels of PTH, unexpected ‘normal calciuria’ and the 
findings in neck ultrasonography. The normalisation of calcium 
values after parathyroidectomy also firms this hypothesis.
Genetic study of our patient detected the variant c.602–16G>A 
and the variant c.2221G>A (p.Gly741Arg), both in heterozygosity, 
in SLC12A3 gene. The variant c.2221G>A (p.Gly741Arg) was 
described in other patients with GS9 10 and is found on dbSNP and 
ExAC databases with a global frequency of 0.040%. It is localised 
in a highly conserved residue and its functional impact was already 
studied. Thus, it should be considered a probably pathogenic 
variant. The variant c.602–16G>A is described on the database 
of HGMD; as a disease-causing mutation,11 it has been identified 
in two different families with GS, in trans with other pathogenic 
mutations. It is also described in dbSNP and ExAC databases with a 
frequency of 0.0016%. However, due to lack of functional studies 
confirming the splicing effect, this variant is considered of undeter-
mined significance.
Genetic study of the parents revealed in the father the variant 
c.602–16G>A and the mother the variant c.2221G>A (p.Gl-
y741Arg), in SLC12A3 gene. The genetic study of the parents 
concluded that the variants found are in different alleles (trans), 
which reinforce their pathogenicity.
GS is a recessively inherited disease, with simple hetero-
zygous relatives being asymptomatic. Nevertheless, there is a 
small percentage of affected individuals with only one mutant 
allele.12 Since the expression of NCC may be influenced by 
epigenetic modifications and/or silent polymorphisms, this may 
lead to impaired function in simple heterozygous.12 Screening of 
electrolyte abnormalities in parents was done and excluded a mild 
phenotype.
The combination of hypokalaemia, hypomagnesaemia 
and hypercalcaemia is uncommon but potentially lethal. To 
our knowledge, there is only one case reported in the litera-
ture. In our patient, initial severe hypomagnesaemia imposed 
carefully Mg2+ reposition, taking into account the risk of 
worsening hypercalcaemia and justified strictly electrolytic 
monitoring.
Molecular study added value since permits the screening 
of the parents and genetic counselling when pregnancy is 
desired.
learning points
 ► Gitelman syndrome (GS) is caused by mutations in 
the SLC12A3 gene.
 ► It is a rare autosomal recessive tubulopathy characterised by 
hypokalaemia, hypomagnesaemia, hypocalciuria, metabolic 
alkalosis and secondary hyperaldosteronism.
 ► Hypercalcaemia due to hypocalciuria in these patients is 
extremely rare. This can be explained by impaired calciotropic 
hormones due to hypomagnesaemia observed in these 
patients.
 ► The presence of hypercalcaemia in the course of GS requires 
further evaluation in order to exclude reversible causes of 
hypercalcaemia.
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